News - Pharmaceutical, Orencia


Current filters:


Popular Filters

Bristol-Myers Squibb records $3.8 billion sales in first quarter

Bristol-Myers Squibb records $3.8 billion sales in first quarter


US drug major Bristol-Myers Squibb has reported its first quarter results showing higher-than-expected…

AstraZenecaBaracludeBristol-Myers SquibbBusiness FinanceBusiness FinanceDapagliflozinFinancialOrenciaPharmaceuticalSprycelUnited StatesUSAYervoy

Product launches to fuel lupus market growth


The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results


Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

German pharma watch dog finds benefits for biologicals in RA


The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData


Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China


US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

NICE green light for earlier use of Bristol-Myers' Orencia


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

UK's NICE draft guidance recommends Bristol-Myers Orencia for RA


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (December…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalPricingRegulation

More news at EULAR from Novartis, J&S and B-MS


Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

US rheumatologists continue to increase use of biologics for RA treatment


Biologic agents remain the preferred treatment for patients suffering from rheumatoid arthritis (RA),…

ActemraAnti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingNorth AmericaOrenciaPharmaceuticalRituxantofacitinib

Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia


US drug major Bristol-Myers Squibb (NYSE:BMY) says it has agreed with Japan’s Ono Pharmaceutical…

Anti-Arthritics/RheumaticsAsia-PacificBristol-Myers SquibbLicensingMarkets & MarketingOncologyOno PharmaceuticalOrenciaPharmaceutical

UK’s NICE recommends Merck & Co’s Simponi but not B-MS’s Orencia


There was mixed news for US drug majors Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) this…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeMerck & CoOrenciaPharmaceuticalPricingRegulationSimponi Injection

US FDA backs SC form of B-MS Orencia; extends review of Pfizer’s Prevnar 13


The US Food and Drug Administration has approved a subcutaneous (SC) formulation of drug major Bristol-Myers…

Anti-Arthritics/RheumaticsBristol-Myers SquibbNorth AmericaOrenciaPfizerPharmaceuticalPrevnarRegulationVaccines

Back to top